These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 14964740)

  • 21. Formulary management: antibiotics and therapeutic interchange.
    Massoomi F
    Pharm Pract Manag Q; 1996 Oct; 16(3):11-8. PubMed ID: 10166231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASHP guidelines on formulary system management.
    Am J Hosp Pharm; 1992 Mar; 49(3):648-52. PubMed ID: 1598948
    [No Abstract]   [Full Text] [Related]  

  • 23. Working with PBMs (pharmacy benefit managers).
    Peterson C
    Healthplan; 1999; 40(2):83-6, 88-9. PubMed ID: 10537477
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 25. Escalating need for comparative analysis of drugs within a therapeutic class.
    Giaquinta D
    Manag Care Interface; 2003 Oct; 16(10):32-4. PubMed ID: 14606258
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic substitution practices in short-term hospitals.
    Doering PL; Klapp DL; McCormick WC; Russell WL
    Am J Hosp Pharm; 1982 Jun; 39(6):1028-32. PubMed ID: 7102686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulary standards key to E-prescribing success.
    Schueth T
    Manag Care; 2004 Oct; 13(10):41-3. PubMed ID: 15535159
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting formulary pull-through strategies: the role of pharmaceutical manufacturers.
    Navarro RP
    Manag Care Interface; 1999 May; 12(5):84-6. PubMed ID: 10537482
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug companies crying foul over Medicaid's formulary push.
    Carroll J
    Manag Care; 2002 Nov; 11(11):12-4. PubMed ID: 12491852
    [No Abstract]   [Full Text] [Related]  

  • 30. Legal implications of the pharmacist's expanded clinical roles: a challenge to the clinical pharmacist's competencies.
    Moore RC; Mikeal RL; Brewer BF; Burton SF
    Contemp Pharm Pract; 1979; 2(3):132-5. PubMed ID: 10297530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
    Wang YR; Pauly MV
    Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American Academy of Pediatrics Committee on Drugs: Generic prescribing, generic substitution, and therapeutic substitution.
    Pediatrics; 1987 May; 79(5):835. PubMed ID: 3575043
    [No Abstract]   [Full Text] [Related]  

  • 33. [Generic drug substitution].
    Tamir O; Halkin H; Shemer J
    Harefuah; 2006 Sep; 145(9):691-5, 701. PubMed ID: 17078434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential and actual drug product selection rates in Florida.
    Vuturo GJ; McCormick WC; Krischer JP
    Contemp Pharm Pract; 1980; 3(3):163-70. PubMed ID: 10247872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current approaches to the use of generic antiepileptic drugs.
    Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G
    Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substitution: expectations and realization.
    Gorrell JM
    Med Mark Media; 1981 May; 16(5):52, 54-7. PubMed ID: 10251529
    [No Abstract]   [Full Text] [Related]  

  • 37. Strategies for developing a successful Medicare part D formulary.
    Stefanacci RG
    Manag Care; 2005 May; 14(5 Suppl):3-10. PubMed ID: 15962831
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
    MacEachern L
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H; Shrank WH
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.